Suchergebnisse - "Ogasawara, Ken"

PubPharm (180)

1

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma : Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Wang, M. | Siddiqi, T. | Gordon, L. | +17

2

Plain language summary of the TRANSFORM study primary analysis results : lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

enthalten in: Future oncology (London, England) | 2024

von Abramson, J. | Solomon, S. | Arnason, J. | +15

3

Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Chen, Y. | Wyatt, D. | Attanasio, M. | +10

4

DOSING OF FEDRATINIB

enthalten in: Europäisches Patentamt | 2024

von KRISHNA GOPAL | OGASAWARA KEN

5

DOSING OF FEDRATINIB

enthalten in: Europäisches Patentamt | 2024

von KRISHNA GOPAL | OGASAWARA KEN

6

Mapping Colorectal Distribution of Cell-free and Cell-associated HIV Surrogates Following Simulated Anal Intercourse to Aid Rectal Microbicide Development

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2024

von Weld, E. | Ogasawara, K. | Fuchs, E. | +3

7

An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development

enthalten in: Clinical pharmacology and therapeutics | 2024

von Gokemeijer, J. | Balasubramanian, N. | Ogasawara, K. | +13

8

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

enthalten in: Blood | 2024

von Abramson, J. | Palomba, M. | Gordon, L. | +14

CommentIn: Blood. 2024 Feb 1;143(5):379-380. - PMID 38300610

9

An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies Development

enthalten in: Clinical Pharmacology & Therapeutics | 2024

von Gokemeijer, J. | Balasubramanian, N. | Ogasawara, K. | +13

10

Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Chen, Y. | Wyatt, D. | Attanasio, M. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]